BioSpace News Archive

New Healthcare Company to Offer Medicare Advantage Plans in 2019

Merck today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO™

Board and Compensation Committee Determine That Separations Be Treated as “For Cause” Terminations Based on Information from Audit Committee’s Ongoing Independent Investigation

FDA analysis finds no new or unexpected safety risks associated with NUPLAZID

Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million Series A financing round.

Kaiser Permanente has the highest performing commercial and Medicare plan (or is tied for the highest) in every geographic region it serves

According to the market research report released by Technavio, the global optical coherence tomography market is expected to accelerate at a CAGR of more than 8% during the forecast period.

Power Rogers & Smith attorneys Todd A. Smith and Brian LaCien are representing Willowbrook families who filed a class action lawsuit against Sterigenics International LLC and GTCR LLC

The collaboration between St. Jude and Tessa aims to advance cellular immunotherapy treatments for childhood cancer

New drug discovery has been limited by researchers’ inability to control a molecules’ 3D structure. But a team of scientists from The Graduate Center of The City University of New York (GC/CUNY) has made a breakthrough in chemical synthesis that now makes it possible to quickly and reliably modify a molecule’s 3D structure, according to a paper in Friday’s issue of Science.